Durability of immunogenicity and strain coverage of MenBvac, a meningococcal vaccine based on outer membrane vesicles: Lessons of the Normandy campaign.

[1]  M. Pizza,et al.  Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England , 2016, Emerging infectious diseases.

[2]  J. Welsch,et al.  Serum bactericidal antibody assays - The role of complement in infection and immunity. , 2015, Vaccine.

[3]  D. Medini,et al.  MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. , 2015, Vaccine.

[4]  Ly-Mee Yu,et al.  Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months , 2015, Canadian Medical Association Journal.

[5]  J. Derrick,et al.  Neisseria meningitidis Native Outer Membrane Vesicles Containing Different Lipopolysaccharide Glycoforms as Adjuvants for Meningococcal and Nonmeningococcal Antigens , 2013, Clinical and Vaccine Immunology.

[6]  J. Leroy,et al.  Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage. , 2013, Vaccine.

[7]  M. Taha,et al.  Meningococcal carriage during a clonal meningococcal B outbreak in France , 2013, European Journal of Clinical Microbiology & Infectious Diseases.

[8]  R. Rappuoli,et al.  Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. , 2013, The Lancet. Infectious diseases.

[9]  M. Pizza,et al.  Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa? , 2013, Vaccine.

[10]  J. Leroy,et al.  Evolution of immune response against Neisseria meningitidis B:14:P1.7,16 before and after the outer membrane vesicle vaccine MenBvac. , 2012, Vaccine.

[11]  D. Levy-bruhl,et al.  From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. , 2011, The Lancet. Infectious diseases.

[12]  D. Stephens.  Outer-membrane-vesicle vaccines: old but not forgotten. , 2011, Lancet. Infectious Diseases (Print).

[13]  A. Pollard,et al.  Serogroup B meningococcal vaccines-an unfinished story. , 2010, The Lancet. Infectious diseases.

[14]  D. Levy-bruhl,et al.  Invasive meningococal disease in France, 2009. , 2009 .

[15]  E. Rosenqvist,et al.  Functional and Specific Antibody Responses in Adult Volunteers in New Zealand Who Were Given One of Two Different Meningococcal Serogroup B Outer Membrane Vesicle Vaccines , 2007, Clinical and Vaccine Immunology.

[16]  J. Poolman,et al.  Immunogenicity and Safety of Three Doses of a Bivalent (B:4:P1.19,15 and B:4:P1.7-2,4) Meningococcal Outer Membrane Vesicle Vaccine in Healthy Adolescents , 2006, Clinical and Vaccine Immunology.

[17]  K. Rasanathan,et al.  Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. , 2006, Vaccine.

[18]  E. Miller,et al.  Meningococcal surrogates of protection--serum bactericidal antibody activity. , 2005, Vaccine.

[19]  R. Rappuoli,et al.  The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease. , 2005, Vaccine.

[20]  K. Mulholland,et al.  The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic. , 2004, The New Zealand medical journal.

[21]  Martin C. J. Maiden,et al.  mlstdbNet – distributed multi-locus sequence typing (MLST) databases , 2004, BMC Bioinformatics.

[22]  J. Tappero,et al.  Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. , 1999, JAMA.

[23]  E. Rosenqvist,et al.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine , 1995, Infection and immunity.

[24]  D. Caugant,et al.  Expression of an inaccessible P1.7 subtype epitope on meningococcal class 1 proteins. , 1993, Journal of medical microbiology.

[25]  A. Halstensen,et al.  Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway , 1991, The Lancet.